Validation Data Gallery
Filter:
Tested Applications
| Positive WB detected in | human placenta tissue |
| Positive IHC detected in | human tonsillitis tissue, human colon cancer tissue, human spleen tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| Immunohistochemistry (IHC) | IHC : 1:300-1:1200 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 2 publications below |
| IHC | See 1 publications below |
Product Information
25278-1-AP targets PR3/PRTN3 in WB, IHC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | PR3/PRTN3 fusion protein Ag16765 相同性解析による交差性が予測される生物種 |
| Full Name | proteinase 3 |
| Calculated molecular weight | 256 aa, 28 kDa |
| Observed molecular weight | 28 kDa |
| GenBank accession number | BC096183 |
| Gene Symbol | PRTN3 |
| Gene ID (NCBI) | 5657 |
| RRID | AB_2880003 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P24158 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for PR3/PRTN3 antibody 25278-1-AP | Download protocol |
| IHC protocol for PR3/PRTN3 antibody 25278-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Front Cell Neurosci Meningitic Escherichia coli-Induced Interleukin-17A Facilitates Blood-Brain Barrier Disruption via Inhibiting Proteinase 3/Protease-Activated Receptor 2 Axis. | ||
Toxicol In Vitro Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events. |